antiarrythmic drugs

Amiodarone - Dronedarone - Flecainide - Lidocaine - Propafenone      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathAtrial fibrillation recurrence

acute myocardial infarction

dofetilide
DIAMOND MI, 1997   dofetilideplaceboLow risk of bias -
magnesium
ISIS-4, 1995   magnesiumcontrolsuggesting 6%
Wu, 1992   magnesiumcontrolLow risk of bias suggesting-66%
Zhu, 2002   magnesiumcontrolsuggesting-34%
Abraham, 1987   magnesiumplaceboLow risk of bias negative-4%
MAGIC, 2000      NCTmagnesiumplaceboLow risk of bias negative0%
Bhargava, 1995     magnesiumplaceboLow risk of bias suggesting-5%
Ceremuzynski, 1989   magnesiumplacebosuggesting-69%
Chen, 1991   magnesiumplacebosuggesting
Feldstedt, 1991     magnesiumplaceboLow risk of bias negative23%
Gyamlani, 2000   magnesiumplaceboLow risk of bias suggesting-80%
Ising, 1990   magnesiumplacebo -
Morton, 1984   magnesiumplaceboLow risk of bias negative -55%
Nakashima, 2004     magnesiumplaceboLow risk of bias negative-66%
Parikka, 1990     magnesiumplaceboLow risk of bias negative
Raghu, 1999     magnesiumplaceboLow risk of bias suggesting-64%
Rasmussen, 1986   magnesiumplaceboLow risk of bias negative-62%
Santoro, 2000   magnesiumplaceboLow risk of bias negative-100%
Shechter, 1990     magnesiumplaceboLow risk of bias suggesting-88%
Shechter, 1991   magnesiumplaceboLow risk of bias negative-40%
Shechter, 1995     magnesiumplaceboLow risk of bias suggesting-76%
Singh, 1990   magnesiumplaceboLow risk of bias suggesting-45%
Smith, 1986   magnesiumplaceboLow risk of bias negative-71%
Thogersen, 1995     magnesiumplaceboLow risk of bias negative-53%
Urek, 1996   magnesiumplaceboLow risk of bias negative+Infini%
Woods, 1992       magnesiumplaceboLow risk of bias suggesting -24%
moricizine
CAST II (early treatment), 1992   moricizineplaceboLow risk of bias -

atrial fibrillation

amiodarone
Channer, 2004     amiodaroneplaceboLow risk of bias suggesting-46%
GEFACA, 2001   amiodaroneplaceboLow risk of bias suggesting-68%
Kochiadakis (amiodarone vs placebo), 2000       amiodaroneplacebosuggesting-47%
SAFE-T (amiodarone vs placebo), 2005       amiodaroneplaceboLow risk of bias suggesting114%-42%
AFFIRM Substudy (amiodarone vs class I drugs), 2003     amiodaroneclass I drugsRisk of bias suggesting-58%-34%
AFFIRM Substudy (sotalol vs class I drugs), 2003     amiodaroneclass I drugs -
Villani, 1992   amiodaronedisopyramidesuggesting-45%
Kochiadakis a, 2004       amiodaronepropafenonenegative -36%
Vitolo, 1981   amiodaronequinidinesuggesting-60%
AFFIRM Substudy (amiodarone vs sotalol), 2003     amiodaronesotalolsuggesting-40%-32%
Kochiadakis (amiodarone vs sotalol), 2000     amiodaronesotalol -
SAFE-T (amiodarone vs sotalol), 2005     amiodaronesotalolLow risk of bias -
Azimilide
ASAP, 2003             AzimilideplaceboLow risk of bias negative 23%
disopyramide
Karlson, 1998     disopyramideplacebonegative+Infini%-25%
Lloyd (Disopyramide vs placebo), 1984   disopyramideplaceboLow risk of bias negative-19%
PRODIS, 1996   disopyramidepropafenoneLow risk of bias negative+Infini%-27%
Lloyd (Disopyramide vs quinidine), 1984   disopyramidequinidineLow risk of bias -
dofetilide
DIAMOND, 2001       dofetilideplaceboLow risk of bias suggesting-1%-38%
SAFIRE-D, 2000     dofetilideplaceboLow risk of bias suggesting-25%-15%
dronedarone
EURIDIS, 2007      NCTdronedaroneplaceboLow risk of bias suggesting-22%
ADONIS, 2007    NCTdronedaroneplaceboLow risk of bias suggesting-27%
DAFNE, 2003     dronedaroneplaceboLow risk of bias suggesting+Infini%-14%
EURIDIS ADONIS (pooled analysis), 2009   dronedaroneplaceboLow risk of bias negative32%
ATHENA, 2009      NCTdronedaroneplaceboLow risk of bias suggesting -16%-34%
PALLAS, 2011        NCTdronedaroneplaceboLow risk of bias negative 128%
ERATO, 2008   dronedaroneplaceboLow risk of bias negative+Infini%
DIONISOS, 2007      NCTdronedaroneamiodaroneLow risk of bias suggesting -59%34%
flecainide
Van Gelder, 1989   flecainideno treatmentnegative-19%
Carunchio (flecainide vs placebo), 1995   flecainideplacebosuggesting-59%
Steinbeck (flecainide vs digoxin), 1988   flecainidedigoxinsuggesting-54%
Aliot, 1996     flecainidepropafenonesuggesting-100%-25%
Naccarelli, 1996     flecainidequinidineLow risk of bias negative 4%
metoprolol
Kuhlkamp, 2000     metoprololplacebonegative +Infini%-9%
propafenone
Bellandi (propafenone vs placebo), 2001     propafenoneplaceboLow risk of bias suggesting-35%
Dogan, 2004   propafenoneplacebosuggesting-100%-31%
Kochiadakis b (propafenone vs placebo), 2004       propafenoneplacebosuggesting-42%
RAFT, 2003     propafenoneplaceboLow risk of bias suggesting-29%
Stroobandt, 1997     propafenoneplaceboLow risk of bias negative-100%-29%
FAPIS, 1996       propafenoneflecainidenegative6%
Richiardi, 1992   propafenonequinidinenegative -100%12%
Reimold, 1993     propafenonesotalolnegative+Infini%-9%
quinidine
Hillestad, 1971     quinidineno treatmentnegative+Infini%-26%
Sodermark, 1975     quinidineno treatmentsuggesting 105%-27%
Lloyd (quinidine vs placebo), 1984   quinidineplaceboLow risk of bias negative+Infini%-16%
PAFAC (quinidine vs placebo), 2004       quinidineplaceboLow risk of bias suggesting5%-22%
SOPAT (quinidine vs placebo), 2004       quinidineplaceboLow risk of bias suggesting+Infini%-11%
Byrne Quinn, 1979     quinidineplaceboLow risk of bias suggesting+Infini%-21%
Steinbeck (quinidine vs digoxin), 1988   quinidinedigoxinnegative-23%
Lloyd (quinidine vs disopyramide), 1984   quinidinedisopyramideLow risk of bias -
Steinbeck (quinidine vs flecainide), 1988   quinidineflecainide -
Hohnloser, 1995     quinidinesotalolnegative -42%
Juul-Moller, 1990   quinidinesotalolnegative 15%13%
Kalusche, 1994   quinidinesotalolnegative+Infini%-29%
SOCESP, 1999     quinidinesotalolnegative-100%15%
PAFAC (quinidine vs sotalol), 2004     quinidinesotalolLow risk of bias -
SOPAT (quinidine vs sotalol), 2004   quinidinesotalolLow risk of bias -
sotalol
Benditt, 1999     sotalolplaceboLow risk of bias negative -2%
Singh, 1991   sotalolplaceboLow risk of bias suggesting-21%
Bellandi (sotalol vs placebo), 2001   sotalolplaceboLow risk of bias suggesting-43%
Carunchio (sotalol vs placebo), 1995   sotalolplacebosuggesting-45%
Kochiadakis (sotalol vs placebo), 2000   sotalolplacebo -
Kochiadakis b (sotalol vs placebo), 2004     sotalolplacebosuggesting-28%
PAFAC (sotalol vs placebo), 2004     sotalolplaceboLow risk of bias suggesting49%-20%
SAFE-T (sotalol vs placebo), 2005       sotalolplaceboLow risk of bias suggesting153%-19%
SOPAT (sotalol vs placebo), 2004   sotalolplaceboLow risk of bias negative+Infini%-8%
Plewan, 2001     sotalolbisoprololnegative7%
Carunchio (sotalol vs flecianide), 1995   sotalolflecainide -
Kochiadakis b (sotalol vs propafenome), 2004   sotalolpropafenone -

cardiac arrest

amiodarone
ARREST, 1999     amiodaroneplaceboLow risk of bias suggesting
ALIVE, 2002     amiodaronelidocaineLow risk of bias suggesting-2%

heart failure

amiodarone
EPAMSA, 1985   amiodaroneno treatmentsuggesting-61%
GESICA, 1994   amiodaroneno treatmentsuggesting-28%
Hamer, 1989   amiodaroneplaceboLow risk of bias suggesting-25%
Nicklas, 1991   amiodaroneplaceboLow risk of bias negative54%
STATCHF, 1995     amiodaroneplaceboLow risk of bias negative-6%
AMIOVIRT, 2003     amiodaroneICDnegative14%
dronedarone
ANDROMEDA, 2008      NCTdronedaroneplaceboLow risk of bias negative 113%

post myocardial infarction

amiodarone
BASIS, 1990   early amiodaronecontrolsuggesting-59%
Navarro-Lopez, 1993   early amiodaronecontrolnegative-52%
CAMIAT , 1991   early amiodaroneplaceboLow risk of bias negative-18%
Ceremuzynski, 1992   early amiodaroneplaceboLow risk of bias negative-37%
Hockings, 1987     early amiodaroneplaceboLow risk of bias negative94%
Azimilide
ALIVE, 2004       azimilideplaceboLow risk of bias -
dofetilide
DIAMOND MI, 1997   dofetilideplaceboLow risk of bias -
moricizine
CAST II (early treatment), 1992   moricizineplaceboLow risk of bias -
CAST II (late treatment), 1992   moricizineplaceboLow risk of bias -